Cargando…

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

AIMS/HYPOTHESIS: To assess the effect of an angiotensin receptor blocker (ARB) on serum potassium and the effect of a serum potassium change on renal outcomes in patients with type 2 diabetes and nephropathy. METHODS: We performed a post hoc analysis in patients with type 2 diabetes participating in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miao, Y., Dobre, D., Lambers Heerspink, H. J., Brenner, B. M., Cooper, M. E., Parving, H-H., Shahinfar, S., Grobbee, D., de Zeeuw, D.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2010
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995871/ https://www.ncbi.nlm.nih.gov/pubmed/20882268 http://dx.doi.org/10.1007/s00125-010-1922-6

Ejemplares similares

Erratum to: Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
por: Miao, Y., et al.
Publicado: (2011)

Losartan and diabetic nephropathy: commentaries on the RENAAL study
por: Fisman, Enrique Z, et al.
Publicado: (2002)

High serum potassium levels after losartan can reflect more severe renal disease. Reply to Gonçalves AR, El Nahas AM [letter]
por: Roscioni, S. S., et al.
Publicado: (2011)

Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria: A post hoc analysis of the IRMA-2 trial
por: Hellemons, Merel E., et al.
Publicado: (2011)

Diminished antiproteinuric effect of the angiotensin receptor blocker losartan during high potassium intake in patients with CKD
por: Wouda, Rosa D, et al.
Publicado: (2021)

The Use of Surrogate Endpoints in Regulating Medicines for Cardio-Renal Disease: Opinions of Stakeholders
por: Schievink, Bauke, et al.
Publicado: (2014)

Heterogeneous Changes of Serum Potassium Levels in NIDDM Patients on Oral Glucose Load
por: Bae, Hak Yeon, et al.
Publicado: (1992)

Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials
por: Idzerda, Nienke M A, et al.
Publicado: (2019)

The Clinical Usefulness of Serum Fructosamine and HbAlc in Patients with NIDDM
por: Lim, Si Young, et al.
Publicado: (1989)

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
por: Heerspink, H J Lambers, et al.
Publicado: (2013)

Hydrochlorothiazide/Losartan Potassium Tablet Prepared by Direct Compression
por: Luo, Qiuhua, et al.
Publicado: (2022)

Improving clinical trial efficiency by biomarker-guided patient selection
por: Boessen, Ruud, et al.
Publicado: (2014)

Genetic Dissection of Complex Genetic Factor Involved in NIDDM of OLETF Rat
por: Yamada, Takahisa, et al.
Publicado: (2012)

Creatinine Excretion Rate and Mortality in Type 2 Diabetes and Nephropathy
por: Sinkeler, Steef J., et al.
Publicado: (2013)

Design and In Vitro Evaluation of Compression-coated Pulsatile Release Tablets of Losartan Potassium
por: Bajpai, M., et al.
Publicado: (2012)

Synthesis and Characterization of Nanoporous Carbon Carriers for Losartan Potassium Delivery
por: Ejsmont, Aleksander, et al.
Publicado: (2021)

Blood pressure‐lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies
por: Olde Engberink, Rik H. G., et al.
Publicado: (2016)

Effect of Angiotensin II Type 1 Receptor Antagonist, Losartan on Inflammatory Factor in Atherosclerotic Rabbits
por: Xu, Yan-min, et al.
Publicado: (2013)

Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra
por: Grammatopoulos, Tom N, et al.
Publicado: (2007)

Mimosa pudica mucilage nanoparticles of losartan potassium: Characterization and pharmacodynamics evaluation
por: Ghumman, Shazia Akram, et al.
Publicado: (2023)

The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma
por: Coulson, Rhiannon, et al.
Publicado: (2017)

The Geographical Distribution of Leadership in Globalized Clinical Trials
por: Hoekman, Jarno, et al.
Publicado: (2012)

Lipotoxic Nephropathy Is More Severe in Male than Female Rats N with Non-Insulin Diabetes Mellitus (NIDDM)
por: Dominguez, Jesus H., et al.
Publicado: (2001)

Preliminary clinical assessment and non- toxicity evaluation of an ayurvedic formulation BGR-34 in NIDDM
por: Gupta, B.P., et al.
Publicado: (2018)

Angiotensin receptor blocker Losartan inhibits tumor growth of colorectal cancer
por: Hashemzehi, Milad, et al.
Publicado: (2021)

Novel Insights into the Antagonistic Effects of Losartan against Angiotensin II/AGTR1 Signaling in Glioblastoma Cells
por: Panza, Salvatore, et al.
Publicado: (2021)

A Method for Content Uniformity Determination of Atenolol and Losartan Potassium in Combined Tablet Dosage Form
por: Shah, S. A., et al.
Publicado: (2010)

Comment on: Ekinci et al. Dietary Salt Intake and Mortality in Patients With Type 2 Diabetes. Diabetes Care 2011;34:703–709
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

Reduced dihydroxyacetone sensitivity and normal sensitivity to glyceraldehyde and oxidizing agent of ATP-sensitive K+ channels of pancreatic beta cells in NIDDM rats.
por: Song, D. K., et al.
Publicado: (1997)

RP-HPLC Method for the Determination of Losartan Potassium and Ramipril in Combined Dosage Form
por: Rao, K. Srinivasa, et al.
Publicado: (2010)

Development and evaluation of chitosan based oral controlled matrix tablets of losartan potassium
por: Rao, Tallapaneni Vishnuvardhan, et al.
Publicado: (2012)

Human Bioequivalence Evaluation of Two Losartan Potassium Tablets Under Fasting Conditions
por: Das, A. K., et al.
Publicado: (2015)

Pharmaceutical Development of Film-Coated Mini-Tablets with Losartan Potassium for Epidermolysis Bullosa
por: Elezaj, Valentinë, et al.
Publicado: (2022)

Postprandial 2-hr C-peptide Concentration as a Guide for Insulin Treatment in Patient with NIDDM
por: Kim, Rhee Sook, et al.
Publicado: (1986)

Monitoring Kidney Function and Albuminuria in Patients With Diabetes
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

Losartan potassium loaded sustained release matrix tablets: Influence of various hydrophilic and hydrophobic polymers on drug release behaviour
por: Vohra, D. D., et al.
Publicado: (2012)

Spectrophotometric and HPLC Methods for Simultaneous Estimation of Amlodipine Besilate, Losartan Potassium and Hydrochlorothiazide in Tablets
por: Wankhede, S. B., et al.
Publicado: (2010)

Sensitive and accurate estimation of losartan potassium formulation by high-performance thin-layer chromatography
por: Selvadurai, Muralidharan, et al.
Publicado: (2011)

Formulation and optimization of mucoadhesive buccal patches of losartan potassium by using response surface methodology
por: Ikram, Md., et al.
Publicado: (2015)

Losartan Potassium and Verapamil Hydrochloride Compound Transdermal Drug Delivery System: Formulation and Characterization
por: Chen, Yu-si, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kmeannr1pq62p6qao7r7s8bnk0